Institutional members access full text with Ovid®

Share this article on:


Srinivas, Sowmya MBBS*; Tan, Ou PhD; Nittala, Muneeswar G. MPhil Opt*; Wu, Jennifer L. MD; Fawzi, Amani A. MD§; Huang, David MD, PhD; Sadda, SriniVas R. MD*,¶

doi: 10.1097/IAE.0000000000001479
Original Study

Purpose: To evaluate retinal blood flow measurements in normal eyes and eyes with varying levels of diabetic retinopathy (DR) using Doppler Fourier-domain optical coherence tomography (FD-OCT).

Methods: Twenty-two eyes of 19 subjects, 10 with severe nonproliferative DR (NPDR) and 12 with proliferative DR (PDR), were compared with 44 eyes of 40 healthy control subjects. All eyes were scanned by RTvue FD-OCT. Color disk photographs and cube/volume scans of the optic nerve head were obtained. Doppler OCT scans and accessory imaging data were imported into Doppler OCT of Retinal Circulation grading software to calculate TRBF and vascular parameters (e.g., venous and arterial cross-sectional area). Measurements were compared between cases and controls using independent t-tests.

Results: Mean TRBF was 44.98 ± 9.80 (range: 30.18–64.58) µL/minute for normal eyes, 35.80 ± 10.48 (range: 20.69–49.56) µL/minute for eyes with severe NPDR, and 34.79 ± 10.61 (range: 16.77–48.9) µL/minute for eyes with PDR. Mean TRBF was significantly lower in eyes with severe NPDR (P = 0.01) and PDR (P = 0.003) than in normal eyes.

Conclusion: Total retinal blood flow was significantly lower in eyes with severe NPDR and PDR compared with normal eyes. Retinal blood flow determined by Doppler OCT may be a useful parameter for evaluating patients with DR.

Doppler optical coherence tomography (OCT) was used to measure total retinal blood flow (TRBF) in normal eyes and eyes with varying levels of diabetic retinopathy (DR). Total retinal blood flow was significantly lower in eyes with nonproliferative diabetic retinopathy and proliferative diabetic retinopathy compared with normal eyes.

*Doppler OCT Reading Center, Doheny Eye Institute, Los Angeles, California;

Casey Eye Institute, Oregon Health & Science University, Portland, Oregon;

Dean McGee Eye Institute, University of Oklahoma, Oklahoma City, Oklahoma;

§Department of Ophthalmology, Northwestern University, Chicago, Illinois; and

Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, California.

Reprint requests: SriniVas R. Sadda, MD, Doheny Eye Institute, 1355 San Pablo Street, Suite 211, Los Angeles, CA 90033; e-mail:

O. Tan receives patent royalties from Optovue and Zeiss, grant supports from Optovue and NIH Grants R01 EY013516, NIH R01 EY023285, NIH DP3 DK104397 and NIH R01 EY024544. D. Huang receives patent royalties from Carl Zeiss Meditec. Inc and Optovue, Inc. Dr. Huang receives stock option ownership, speaker travel support, research grant, and material support from Optovue, Inc. Dr Huang has grant support from NIH Grants R01 EY013516, NIH R01 EY023285, NIH DP3 DK104397, and NIH R01 EY024544.

Presented as a poster in Proceedings of The Association for Research in Vision and Ophthalmology Symposium held on 5 to 9 May 2013 at Seattle, WA.

S. R. Sadda is a coinventor of Doheny intellectual property related to optical coherence tomography that has been licensed by Topcon Medical Systems and is a member of the scientific advisory board for Heidelberg Engineering. Dr. Sadda receives research support from and serves as a consultant for Allergan, Carl Zeiss Meditec, Genentech, and Optos. He has also served as a consultant for Alcon, Novartis, and Roche.

© 2017 by Ophthalmic Communications Society, Inc.